 ChromaDex Corp. NASDAQ:CDXC today announced the results of a new preclinical study published in Nature Scientific Reports investigating the role of Niagen patented nicotinamide riboside in addressing social deficits in Autism Spectrum Disorder ASD. This new study joins a growing body of preclinical data demonstrating that boosting NAD nicotinamide adenine dinucleotide levels may have a positive effect on cognitive health. The study was the first to evaluate Niagen in an Autism model. 